SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015074
Filing Date
2024-11-08
Accepted
2024-11-08 17:08:30
Documents
63
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20240930x10q.htm   iXBRL 10-Q 1173500
2 EX-31.1 anvs-20240930xex31d1.htm EX-31.1 12910
3 EX-32.1 anvs-20240930xex32d1.htm EX-32.1 5567
  Complete submission text file 0001558370-24-015074.txt   5510811

Data Files

Seq Description Document Type Size
4 EX-101.SCH anvs-20240930.xsd EX-101.SCH 39434
5 EX-101.CAL anvs-20240930_cal.xml EX-101.CAL 30483
6 EX-101.DEF anvs-20240930_def.xml EX-101.DEF 142616
7 EX-101.LAB anvs-20240930_lab.xml EX-101.LAB 318576
8 EX-101.PRE anvs-20240930_pre.xml EX-101.PRE 255884
66 EXTRACTED XBRL INSTANCE DOCUMENT anvs-20240930x10q_htm.xml XML 960448
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 241441714
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)